Updated:
Veracyte
Veracyte operates from South San Francisco with additional sites in San Diego, Austin, and Haifa, Israel.
Veracyte
Veracyte operates from South San Francisco with additional sites in San Diego, Austin, and Haifa, Israel. The firm positions itself as a diagnostics company that transforms cancer uncertainty into clinical clarity, fielding a portfolio of tissue and liquid-based tests across the cancer care continuum. Its commercial engine spans five named tumor types. The Afirma Genomic Sequencing Classifier rules out malignancy in thyroid nodules. Decipher Prostate and Decipher Bladder inform risk stratification and treatment decisions for genitourinary cancers. Prosigna calculates the risk of recurrence for early-stage breast cancer, and the TrueMRD test monitors for minimal residual disease in muscle-invasive bladder cancer. A pipeline candidate, the Percepta Nasal Swab, aims to assess lung cancer risk from a simple nasal brushing. The firm cites more than 600 peer-reviewed publications validating these tools and notes involvement in over 35 Phase 2 and 3 trials. The diagnostics platform pairs whole-transcriptome and whole-genome data with machine learning to generate clinical insights. Veracyte disclosed serving more than 800,000 patients as of December 2025. In May 2026, the firm announced that Medicare would cover its TrueMRD monitoring test for muscle-invasive bladder cancer. That same month, the OPTIMA trial delivered evidence that the Prosigna test can identify high-risk breast cancer patients who may safely avoid chemotherapy. Veracyte's structural position depends on clinical-practice penetration. The Decipher Prostate Genomic Classifier remains the only gene-expression test explicitly included in the NCCN Guidelines for prostate cancer. That embeddedness — inside the guideline committees that define standard of care — makes it harder for a new entrant to displace the tests purely on price or analytical performance alone.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
South San Francisco
Corporate office
6000 Shoreline Court, Suite 300, South San Francisco, CA 94080, United States
Additional offices
San Diego, CA, United States · Austin, TX, United States · Haifa, Israel
Sector focus
Frequently asked questions
Which cancer types does Veracyte's commercial portfolio cover?
Veracyte's menu addresses thyroid, prostate, bladder, and breast cancer. The Afirma test assesses thyroid nodule malignancy risk, the Decipher Prostate and Bladder classifiers inform genitourinary treatment decisions, Prosigna provides a breast cancer recurrence score, and TrueMRD monitors muscle-invasive bladder cancer for residual disease. A lung cancer risk-assessment test, the Percepta Nasal Swab, remains in the pipeline.
How does Veracyte generate clinical evidence for its tests?
The firm runs a diagnostics platform that combines whole-transcriptome and whole-genome analysis with machine learning and clinical-outcome data. Veracyte reports more than 600 peer-reviewed publications supporting its tests and involvement in over 35 Phase 2 and 3 trials. Recent evidence includes the May 2026 OPTIMA trial, which showed that the Prosigna test can identify high-risk breast cancer patients who may safely avoid chemotherapy.
What regulatory or guideline status do Veracyte's tests hold?
Most of Veracyte's tests are offered as CLIA-validated laboratory developed tests and do not require FDA clearance in the United States. The Decipher Prostate Genomic Classifier is the only gene-expression test referenced in the NCCN Clinical Practice Guidelines in Oncology for prostate cancer. Outside the U.S., the Prosigna assay is available as a CE-IVD test.
Does Veracyte compete with liquid-biopsy or next-generation sequencing platforms?
Veracyte occupies a specific niche: tissue-based and limited liquid-based genomic classifiers that answer a discrete clinical question — such as whether to proceed to surgery, use chemotherapy, or escalate treatment — rather than broad panel sequencing. Its TrueMRD test does enter the ctDNA minimal-residual-disease monitoring space but is currently confined to muscle-invasive bladder cancer.
Where is Veracyte's testing performed and where does it sell?
The firm operates laboratory and office facilities in South San Francisco, San Diego, Austin, and Haifa, Israel. Its tests are primarily sold in the United States, with the Prosigna assay available as a CE-IVD test outside the U.S. Customer support lines are staffed during U.S. West Coast business hours.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: